Anixa Biosciences (ANIX) Competitors

COMPASS Pathways (NASDAQ:CMPS) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.

Does the media refer more to CMPS or ANIX?

In the previous week, COMPASS Pathways had 6 more articles in the media than Anixa Biosciences. MarketBeat recorded 8 mentions for COMPASS Pathways and 2 mentions for Anixa Biosciences. COMPASS Pathways' average media sentiment score of 1.31 beat Anixa Biosciences' score of 0.93 indicating that COMPASS Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
COMPASS Pathways	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in CMPS or ANIX?

COMPASS Pathways received 34 more outperform votes than Anixa Biosciences when rated by MarketBeat users. Likewise, 81.48% of users gave COMPASS Pathways an outperform vote while only 76.19% of users gave Anixa Biosciences an outperform vote.

Company	Underperform	Outperform
COMPASS Pathways	Outperform Votes 66 81.48%	Underperform Votes 15 18.52%
Anixa Biosciences	Outperform Votes 32 76.19%	Underperform Votes 10 23.81%

Do insiders and institutionals hold more shares of CMPS or ANIX?

46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by company insiders. Comparatively, 25.3% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is CMPS or ANIX more profitable?

Anixa Biosciences' return on equity of -58.55% beat COMPASS Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	-63.85%	-51.97%
Anixa Biosciences	N/A	-58.55%	-53.29%

Do analysts recommend CMPS or ANIX?

COMPASS Pathways currently has a consensus price target of $20.20, indicating a potential upside of 393.28%. Anixa Biosciences has a consensus price target of $9.00, indicating a potential upside of 220.86%. Given COMPASS Pathways' higher probable upside, equities research analysts clearly believe COMPASS Pathways is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Anixa Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has better valuation & earnings, CMPS or ANIX?

Anixa Biosciences has higher revenue and earnings than COMPASS Pathways. Anixa Biosciences is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	-$118.46M	-$2.30	-1.78
Anixa Biosciences	$210K	430.06	-$12.55M	-$0.39	-7.19

Which has more volatility & risk, CMPS or ANIX?

COMPASS Pathways has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

COMPASS Pathways beats Anixa Biosciences on 10 of the 17 factors compared between the two stocks.